Prognostic Cancer ModelNCT06308354
Colorectal Cancer Dataset in Xijing Hospital From 2011
An observational study of Prognostic Cancer Model and Chemotherapy, run by Xijing Hospital at 1 site in China.
Trial summary
To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Prognostic Cancer Model, Chemotherapy, Nutrition Related Cancer
- How many people
- 40,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2011to 1 Jan 2048
- How long will I take part?
- 10 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- Adult, Older adult
Study population: Colorectal cancer patients mainly comes from the western areas of China, and would accept the surgical procedures. Participate would be followed up every 6 months after surgery.
Who may be able to join
- 1. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;
- 2. Visit our center with complete medical records and pathological information;
- 3. Colorectal cancer patients diagnosed between 2013 and 2023.
Who cannot join
- 1. The patient has other colorectal malignancies other than adenocarcinoma;
- 2. Malignant tumors adjacent to organs invading the colon and rectum;
- 3. Malignant tumors from distant organs metastasize to the colon and rectum;
- 4. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Fourth Military Medical University
Xi'an, Shaanxi
Jipeng Li, +86-029-84771533
About this study
To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| colorectal cancer | Colorectal cancer patients are enrolled when patients were underwent surgeries. |
What is being measured
The primary outcome is the main question the study is designed to answer.
overall survival
to dead or lost to follow
Measured: from date of diagnosis until the date of death from any cause, assessed up to 120 months
DFS
disease-free survival
Measured: from date of diagnosis until the first documented progression or recurrence, assessed up to 120 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Mar 2024
- Study start1 Jan 2011
- Primary completion1 Jan 2048 (estimated)
- Study completion1 Jan 2048 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Prognostic Cancer ModelStudies of the same condition, open and under way.
- More trials run by Xijing HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Xijing Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06308354
- Sponsor's protocol ID
- CRC dataset
- Status last verified
- Jan 2024
- First submitted
- 18 Feb 2024
- Last updated
- 13 Mar 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: The investigators aim to explore the clinical characteristics of colorectal cancer patients in the Xijing hospital.
Publications
Cao S, Qiao Y, Wu L, Chen Q, Tian K, Li J, Xing C. Postoperative adjuvant chemotherapy in patients with stage II early onset colorectal cancer: exploration and discovery using real-world data and the SEER database. Front Oncol. 2025 May 30;15:1566569. doi: 10.3389/fonc.2025.1566569. eCollection 2025.
PubMed 40519292
Study at a glance
From the registry record, last updated by the sponsor on 13 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Colorectal Cancer Dataset in Xijing Hospital From 2011
- ClinicalTrials.gov ID
- NCT06308354
- Acronym / sponsor ID
- CRC dataset
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40,000 participants (estimated)
- Lead sponsor
- Xijing HospitalUniversity, hospital or other
- Study start
- 1 Jan 2011 (actual)
- Primary completion
- 1 Jan 2048 (estimated)
- Study completion
- 1 Jan 2048 (estimated)
- First posted
- 13 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 10 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| colorectal cancer | – | –Colorectal cancer patients are enrolled when patients were underwent surgeries. |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Colorectal cancer patients mainly comes from the western areas of China, and would accept the surgical procedures. Participate would be followed up every 6 months after surgery.
Key inclusion criteria (3 listed)
- 1. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;
- 2. Visit our center with complete medical records and pathological information;
- 3. Colorectal cancer patients diagnosed between 2013 and 2023.
Key exclusion criteria (4 listed)
- 1. The patient has other colorectal malignancies other than adenocarcinoma;
- 2. Malignant tumors adjacent to organs invading the colon and rectum;
- 3. Malignant tumors from distant organs metastasize to the colon and rectum;
- 4. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
overall survival
Time frame: from date of diagnosis until the date of death from any cause, assessed up to 120 months
to dead or lost to follow
DFS
Time frame: from date of diagnosis until the first documented progression or recurrence, assessed up to 120 months
disease-free survival
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Mar 2024.
- Derived from this study: PubMed 40519292Cao S, Qiao Y, Wu L, Chen Q, Tian K, Li J, Xing C. Postoperative adjuvant chemotherapy in patients with stage II early onset colorectal cancer: exploration and discovery using real-world data and the SEER database. Front Oncol. 2025 May 30;15:1566569. doi: 10.3389/fonc.2025.1566569. eCollection 2025.
- Individual participant dataSharing planned: No. The investigators aim to explore the clinical characteristics of colorectal cancer patients in the Xijing hospital.
Related trials for Prognostic Cancer Model
Active, not recruitingPhase 2
Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery
Pancreatic Cancer, Circulating Tumor Cell
RecruitingObservational study
Tissue Collection for Studies of Lymph Cancer
Hodgkin Disease, Lymphoma, Non-Hodgkin
Active, not recruitingObservational study
Prospective Validation of an EHR-based Pancreatic Cancer Risk Model
Pancreatic Adenocarcinoma, Predictive Cancer Model
Active, not recruitingObservational study
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Active, not recruitingObservational study
Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST
Duodenal, Gastrointestinal Stromal Tumors
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Prognostic Cancer Model and Chemotherapy, run by Xijing Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
overall survival (time frame: from date of diagnosis until the date of death from any cause, assessed up to 120 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06308354, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2024.